Hikma Pharmaceuticals Plc Notice of Results (2464T)
16 Luglio 2020 - 1:06PM
UK Regulatory
TIDMHIK
RNS Number : 2464T
Hikma Pharmaceuticals Plc
16 July 2020
London, July 16, 2020 - Hikma Pharmaceuticals PLC (Hikma), will
announce its interim financial results for the six months ended 30
June 2020 on Friday 7 August 2020.
A recording of the presentation will be available on the
Company's website at www.hikma.com from 8:00am BST. Hikma will also
hold a live Q&A conference call for analysts at 9:30am BST, and
a recording will be made available on the Company's website later
that day.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
EVP, Strategic Planning and Global +44 (0)20 7399 2760/ +44 7776
Affairs 477050
Teneo
Charles Armitstead +44 (0)7703 330 269
Camilla Cunningham + 44 (0) 7464 982426
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (LEI:549300BNS685UXH4JI75) (rated Ba1/stable Moody's and
BBB-/stable S&P)
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORGZGMNMVKGGZM
(END) Dow Jones Newswires
July 16, 2020 07:06 ET (11:06 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024